Skip to main content
hello world

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital

PR Newswire - Tue Jun 20, 2023

Program advances to lead compound evaluation in preclinical in vivo models

Preliminary data for in vivo studies are expected in second half of 2023

SAN DIEGO, June 20, 2023 /PRNewswire/ -- Regulus Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced an update on its preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease). Regulus is pursuing this effort in collaboration with the laboratories of Oleg Butovsky, Ph.D., and Howard L. Weiner, M.D., at Brigham and Women's Hospital (BWH) and the Foundation for Neurologic Diseases (Boston, MA). The early-stage collaboration began in September 2021, and has now advanced to evaluation of compounds of interest in ALS preclinical in vivo models. 

Read more at prnewswire.com